Giorgio Valabrega

Turin, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 115 publications

Inavolisib for PIK3CA-mutated advanced endometrial cancer: a multicentric, phase II, MITO END-4 trial.

Inavolisib for PIK3CA-mutated advanced endometrial cancer: a multicentric, phase II, MITO END-4 trial.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: April 27, 2026

The TRUST trial in ovarian cancer: a missed opportunity or a turning point? The position of the Italian MITO group.

The TRUST trial in ovarian cancer: a missed opportunity or a turning point? The position of the Italian MITO group.

Journal: Frontiers in oncology

Published: April 11, 2026

Four-year survival outcomes with dostarlimab plus chemotherapy in mismatch repair deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer in the RUBY trial.

Four-year survival outcomes with dostarlimab plus chemotherapy in mismatch repair deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer in the RUBY trial.

Journal: Gynecologic oncology

Published: March 24, 2026

Poly(adenosine diphosphate-ribose) polymerase inhibitor maintenance therapy with niraparib in patients with primary advanced or recurrent endometrial cancer receiving dostarlimab plus chemotherapy.

Poly(adenosine diphosphate-ribose) polymerase inhibitor maintenance therapy with niraparib in patients with primary advanced or recurrent endometrial cancer receiving dostarlimab plus chemotherapy.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: February 04, 2026

Repurposed Acarbose Targets Nidogen-1 to Remodel the Tumor Stroma and Suppress Portal Vein Tumor Thrombus in Hepatocellular Carcinoma.

Repurposed Acarbose Targets Nidogen-1 to Remodel the Tumor Stroma and Suppress Portal Vein Tumor Thrombus in Hepatocellular Carcinoma.

Journal: Research (Washington, D.C.)

Published: November 20, 2025

PARPi and myeloid neoplasms; the Italian MITO-MaNGO experience based on a multicentric survey.

PARPi and myeloid neoplasms; the Italian MITO-MaNGO experience based on a multicentric survey.

Journal: ESMO open

Published: August 20, 2025

Time tO last ChemotherApy and death in ovaRian cancEr patients: TO CARE/MITO 42 study, a retrospective analysis of italian MITO centers.

Time tO last ChemotherApy and death in ovaRian cancEr patients: TO CARE/MITO 42 study, a retrospective analysis of italian MITO centers.

Journal: Frontiers in oncology

Published: June 05, 2025

Pseudoprogression and improvement of quality of life in a patient with advanced endometrial cancer treated with immunotherapy: a case report.

Pseudoprogression and improvement of quality of life in a patient with advanced endometrial cancer treated with immunotherapy: a case report.

Journal: Drugs in context

Published: April 15, 2025

Peripheral Thyroid Hormones, Inflammatory and Skeletal Muscle Indexes in Advanced Cervical Cancer Treated With Cemiplimab.

Peripheral Thyroid Hormones, Inflammatory and Skeletal Muscle Indexes in Advanced Cervical Cancer Treated With Cemiplimab.

Journal: Journal of cachexia, sarcopenia and muscle

Published: February 13, 2025

Physician knowledge, use, and perceptions of genetic biomarker testing for the management of patients with newly diagnosed advanced ovarian cancer: an international physician survey.

Physician knowledge, use, and perceptions of genetic biomarker testing for the management of patients with newly diagnosed advanced ovarian cancer: an international physician survey.

Journal: Future oncology (London, England)

Published: January 16, 2025

Oncolytic Viruses in Ovarian Cancer: Where Do We Stand? A Narrative Review.

Oncolytic Viruses in Ovarian Cancer: Where Do We Stand? A Narrative Review.

Journal: Pathogens (Basel, Switzerland)

Published: January 06, 2025

A plain language summary publication of patients' survival with endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel.

A plain language summary publication of patients' survival with endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel.

Journal: Therapeutic advances in medical oncology

Published: December 20, 2024

Showing 1-12 of 115

Last Updated: 09/26/2026